Narcolepsy genetic marker HLA DQB1*06:02 and excessive daytime sleepiness in Parkinson disease patients treated with dopaminergic agents - Journal of Neurology
Source : https://link.springer.com/article/10.1007/s00415-021-10813-1
Objective To determine whether narcolepsy Human Leukocyte Antigen (HLA) risk allele DQB1*0602 is associated with excessive daytime sleepiness (EDS) and inappropriate sleep in patients with Parkinson disease (PD). Background EDS...
Conclusion
PD individuals are more likely to experience EDS and fall asleep inappropriately during activities if DQB1*0602 positive. Genetic vulnerability may explain EDS risk in PD.
Disrupted nighttime sleep and sleep instability in narcolepsy
Source : https://doi.org/10.5664/jcsm.9638
This review aimed to summarize current knowledge about disrupted nighttime sleep (DNS) and sleep instability in narcolepsy, including self-reported and objective assessments, potential causes of sleep instability, health consequences and...
CONCLUSIONS:DNS is a common symptom of narcolepsy deserving consideration in clinical care and future research.
Saikosaponin a promotes sleep by decreasing neuronal activities in the lateral hypothalamus
Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/jsr.13484
Yu-Heng Zhong , Shan Jiang , Wei-Min Qu , Wen Zhang , Zhi-Li Huang , Chang-Rui Chen , Corresponding Author Department of Pharmacology, School of Basic Medical Sciences, State Key...
Clinical Characteristics, Iron Metabolism and Neuroinflammation: New I | NDT
Excessive daytime sleepiness (EDS) is very common in Parkinson's disease (PD). Studies report that the prevalence of EDS in PD patients ranges from 16% to 74%. Dopaminergic treatment, severity stages,...
-
Dr Hamid4yrblepharospasm may exhibit abnormal sleep-wake patterns and further support the clinical heterogeneity of the disease.